Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modifie...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2005-03, Vol.23 (17), p.2273-2279
Main Authors: Czub, Markus, Weingartl, Hana, Czub, Stefanie, He, Runtao, Cao, Jingxin
Format: Article
Language:English
Subjects:
Animals
Antigens, Viral - genetics
Applied microbiology
Base Sequence
Biological and medical sciences
DNA, Viral - genetics
Feces
Ferrets
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis, Viral, Animal - pathology
Hepatitis, Viral, Animal - prevention & control
Immunization
Laboratories
Male
Membrane Glycoproteins - genetics
Membrane Glycoproteins - immunology
Microbiology
Miscellaneous
Nucleocapsid Proteins - genetics
Nucleocapsid Proteins - immunology
Proteins
RNA, Viral - analysis
RNA, Viral - genetics
SARS
SARS coronavirus
SARS Virus - genetics
SARS Virus - immunology
SARS Virus - isolation & purification
Severe Acute Respiratory Syndrome - pathology
Severe Acute Respiratory Syndrome - prevention & control
Spike Glycoprotein, Coronavirus
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Synthetic - genetics
Vaccines, Synthetic - pharmacology
Vaccinia virus
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Vaccines - genetics
Viral Vaccines - pharmacology
Virology
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2005.01.033